Passive immunotherapy with monoclonal antibodies has improved outcome for patients with B cell malignancies although many still relapse and little progress has been made with T cell malignancies. Novel treatment approaches are clearly required in this disease setting. There has been much recent interest in developing therapeutic approaches to enhance anti-tumor immune responses by using novel immunomodulatory agents in combination with "standard" of care treatments. Here, we report that intravenous administration of the TOLL-like receptor (TLR)-7 agonist, R848 in combination with radiation therapy (RT) leads to the long standing clearance of tumor in T and B cell lymphoma bearing mice. In combination, TLR7 / RT therapy leads to the expansion of tumor antigen-specific CD8 + T cells and improved survival.
Introduction
Passive immunotherapy with monoclonal antibodies have improved the outcome for patients in a wide range of B cell malignancies 1 . Despite this success little or no progress has been made with T cell lymphoma and furthermore many patients with B cell lymphoma continue to relapse and develop progressive disease following treatment 2 . Clearly additional therapeutic approaches are urgently required. TLRs recognise a diverse repertoire of highly evolutionarily conserved pathogen-associated molecular patterns (PAMPs) present on foreign pathogens and are constitutively expressed by both professional antigen presenting cells (APCs) such as the dendritic cell (DC) and macrophage, and by effector B, T and natural killer (NK) cell populations [8] [9] [10] . Signalling through individual TLRs can direct the phenotype of the ensuing immune response through modulation of cytokine production and polarisation of CD4 + helper, CD8 + effector and T Reg cell responses [11] [12] [13] . Agonism of TLR7, which is localised intracellularly to endosomal membranes by viral guanosine and/or uridine-rich single-stranded RNA, or by synthetic agonists, can engender strong T H -1 biased immune responses through the activation of plasmacytoid DC and myeloid DC subsets 14, 15 . This phenotype of response is optimal for eliciting durable anti-tumor immune responses as it supports the activation and expansion of CD8 + T cells. Currently, Imiquimod (Aldara 5% cream, 3M) is the only
For personal use only. on April 15, 2017 . by guest www.bloodjournal.org From TLR7/8 agonist to receive FDA approval and is licensed in oncology for the topical treatment of basal-cell carcinoma and other dermatological malignancies (reviewed in 16 ). With the exception of therapeutic vaccination approaches, topical administration of TLR agonists are of limited utility in the treatment of the majority of solid tumors and in settings of non-dermatological disseminated disease.
In this study we have investigated intravenous administration of the TLR-7 agonist R848 in combination with radiation therapy (RT) in syngeneic models of T and B cell lymphoma. We hypothesized that the combination of a systemically 
Methods
Mice and cell lines. C57Bl/6 and BALB/c mice were obtained from Harlan, U.K.. All animal experiments were approved by a local ethical committee and performed under a United Kingdom Home Office license. The B cell lymphoma line A20, the T cell lymphoma line EL4 and its ovalbumin expressing derivative EG7 were obtained from ATCC and maintained in RPMI-1640 medium supplemented with 10 % FCS, 1 % Lglutamine (Invitrogen, U.K.) and 50 μ M 2-ME (Sigma, U.K.). EG7 media was also supplemented with 0.5 mg/ml G418 (Invitrogen, U.K. In previous published studies, R848 has been administered locally either by subcutaneous/intra-tumoral injection or by transdermal absorption. To determine whether i.v dosing of R848 had the capacity to induce systemic immune activation in tumorbearing mice, spleens and plasma were harvested 2 and 4 hours after a single i.v. treatment. R848 was well tolerated when dosed systemically at 3 mg/kg and induced the expression of the early activation marker CD69 on T (Fig. 1A) and B (Fig. 1B) lymphocytes at both 2 and 4 hours after dosing when compared to vehicle-treated controls (P < 0.001 two-tailed Student's t test). The systemic induction of cytokines in the serum of treated and control mice were also measured by multiplex bead array (Fig. 1C) . We found that 2 hours after i.v. administration of R848, plasma concentrations of IL-5 increased by 7 fold, IL-6 by approximately 3000 fold and levels of TNFα, undetectable in untreated mice, also increased significantly (P < 0.001 two-tailed Student's t test). By 4 hours, levels of IL-6 had dropped by approximately 10 fold but remained 360 fold higher than in time-matched vehicletreated mice. In addition, the expression of TNFα had dropped down to baseline levels and expression of the T H 1 cytokine IFNγ was found to be significantly elevated (P < 0.01 two-tailed Student's t test).
To determine whether systemic delivery of a TLR7 agonist could lead to therapeutic anti-tumor responses, mice bearing EG7 tumors were treated with either a single or weekly i.v. dose of R848 as a monotherapy. Our data demonstrated that whilst ineffective at controlling tumor growth when administered as a single dose (P (Fig. 1D) . Using MTS and annexin V/PI assays we confirmed in vitro that R848 was not directly affecting the proliferation or viability of the tumor cells (Supplemental Fig. S1A and B) , suggesting that the anti-tumor activity of systemic TLR7 therapy may have been immune mediated. These data demonstrate that i.v. administration of R848 leads to activation of T and B cells commensurate with the origination of a pro-inflammatory cytokine milieu in tumor bearing mice and that monotherapy with R848 provides a modest increase in the survival of EG7
tumor-bearing mice.
R848 in combination with RT improves survival in a model of T cell lymphoma.
Local RT delivered as a single 10 Gy dose to the tumor improves long-term survival in mice bearing sub-cutaneously implanted EG7 tumor ( Fig. 2A) (P < 0.05 Log-rank (Mantel-Cox) test). The anti-tumor efficacy was however substantially improved with systemic administration of R848 in combination with RT ( Fig. 2A and B) . R848 when dosed q1w for 5 weeks but not as a single i.v. dose in combination with RT enhances the efficacy of local RT leading to a substantial increase in the frequency of long-term surviving (LTS) mice (defined as mice surviving greater than 60 days post therapy) when compared to both control mice (75 % of mice classified as LTS following treatment with RT and R848 q1w vs. 4% of control mice) (P < 0.001 Log-rank (Mantel-Cox) test) and to mice receiving monotherapy with either 10 Gy RT or R848 dosed q1w (75 % of mice classified as LTS following treatment with RT and R848 q1w vs. 25 % of mice treated with either monotherapy alone) (P < 0.05 Log-rank (Mantel-Cox) test) ( Fig. 2A and B) . This data demonstrates that the therapeutic For personal use only. on April 15, 2017 . by guest www.bloodjournal.org From efficacy of RT and the ability to bring about long-term tumor control can be substantially augmented by combination with a systemically delivered TLR7 agonist.
Long-term clearance of tumor with R848 and RT is CD8
+ T cell dependent.
We next investigated the mechanisms underlying this long-term tumor control observed following combination RT and R848 therapy. Initially colony forming assays were used to confirm that R848 was not acting as a radiation sensitizer directly through interaction with the tumor cells. We found that addition of 10 μ M R848 to EG7 or EL4 cells irradiated at doses of up to 10 Gy in vitro did not effect clonogenic survival when compared to irradiation alone (Supplemental Fig. S2A and B). As the systemic administration of R848 leads to the potent activation of B lymphocytes ( RT and R848 and non-treated control mice (P > 0.05 two-tailed Student's t test).
Using depleting antibodies we explored the role of effector T cells in mediating the efficacy of combination RT and R848 therapy in the EG7 model. Whilst the depletion of CD4 T lymphocytes had no effect (data not shown), the depletion of CD8 + T cells completely abrogated the therapeutic efficacy of combination RT and TLR7 agonist therapy (Fig. 3C) . Depletion of CD8 + T lymphocytes was confirmed by flow cytometry on peripheral blood samples (Supplemental Fig. S3B ).
RT is one of a number of effective anti-cancer treatments that result in cellular stress and the expression of a plethora of damage-associated molecular patterns S4A ), they were not able to induce DC maturation and no change was observed in the activation markers CD80 or CD86
(P > 0.05 two-tailed Student's t test) (Supplemental Fig. S4B ). The addition of 1 μ g/ml R848 to the co-culture medium led to potent activation of DCs; as evidenced by increased expression of CD80 and CD86, whilst maintaining a high degree of Fig. S4A and B) . Taken together these data demonstrate that the efficacy of combination therapy with RT and R848 is dependent on the activity of CD8 + T cells and that in the absence of TLR7 agonism the outcome of DC interaction with irradiated tumor cells may not be sufficient to drive both their maturation and subsequent ability to prime therapeutic anti-tumor CTL responses.
Treatment with R848 and radiotherapy generates long-lived memory T cells specific for multiple tumor-associated antigens.
We next investigated whether immunological memory was engendered in mice treated with 10 Gy and R848 dosed q1w by harvesting splenocytes from LTS mice that had greater than 150 days of disease free survival (Fig. 4A) and then assessing the capacity of CD8 + CTL to produce IFNγ following co-culture with irradiated EG7 cells (Fig. 4B) . We found that splenocytes from LTS mice had a significantly greater frequency of IFNγ-producing CD8 + T lymphocytes following co-culture than that of tumor naïve controls (10.06 % ± 1.44 vs 3.02 % ± 0.48 respectively; P < 0.01, twotailed Student's t test). To determine whether these memory immune responses were SIINFEKL-restricted, splenocytes were also co-cultured with SIINFEKL peptide for 5 days and then restimulated with irradiated EG7 cells for 16 hours (Fig. 4C) . Although there was an increase in the frequency of SIINFEKL-restricted memory IFNγ + CD8 + lymphocytes in mice treated with combination TLR7 and RT (3.54 % ± 1.47
(combination) vs 0.62 % ± 0.2 (control)) this was not significant (P = 0.12, two-tailed Student's t test). These data suggest that the immune response generated following combination RT and R848 therapy is not restricted to the usually immuno-dominant OVA epitope SIINFEKL, and may be specific for multiple tumor-associated antigens.
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To test this hypothesis, LTS mice originally treated with RT in combination with R848; dosed q1w for 5 weeks, were rechallenged subcutaneously with either EG7 cells or the parental cell line EL4 (which lack expression of OVA). We found that all of the LTS mice were able to completely reject the implanted EG7 cells following contralateral rechallenge (data not shown). When LTS mice originally treated with combination RT and R848 were instead rechallenged with the parental cell line EL4, tumor growth was found to be significantly retarded (P < 0.01 Mann Whitney test) when compared to the naïve control mice (Fig. 4D) . This data demonstrates that in addition to OVA-restricted T cell responses, memory T cells specific for an as yet undefined shared EL4/EG7 tumor-associated antigen(s) were also induced following TLR7 and RT.
Radiation dose-fractionation further enhances the efficacy of combination RT and R848.
Combination therapy with R848 dosed q1w and local RT delivered as a single 10 Gy fraction decreased tumor growth and increased long-term survival significantly when compared to non-treated control mice in both the EG7 (described above; Fig. 2B ) and EL4 models (Fig. 5A and B) (P < 0.01, Log-rank (Mantel-Cox) test). However, unlike the therapeutic response observed in the EG7 model where 75 % of mice were able to completely reject their tumor following treatment with local RT and R848 (dosed q1w), only 15 % of EL4 tumor-bearing mice, which lack the expression of OVA were able to completely reject their tumors. There was a modest increase in survival in EL4
tumor-bearing mice treated with R848 and a single 10 Gy fraction versus monotherapy (P = 0.058, Log-rank (Mantel-Cox) test). Based on recent reports describing the greater immunogenicity of fractionated radiotherapy when compared to induce DC activation in our model system. Likewise we found that in situ vaccination using RT was rarely able to engender an immune response in vivo with the capacity to reject an established tumor ( Fig. 2A) . This latter observation is entirely in keeping with other published studies in a variety of tumor models 3, 20 and is presumably a consequence of tumor-derived immunosuppression; a characteristic of both clinical As the systemic administration of R848 leads to the activation of both B and T lymphocytes we employed depleting monoclonal antibodies to CD20, CD4 and CD8
to delineate the role of these important immune effector cells. Importantly we observed that CD8 but not CD4 T cell or CD20 B cell depletion completely abrogated the therapeutic efficacy of the R848/RT combination. Tumor reactive, SIINFEKLrestricted CTLs could be detected in the circulation for at least 10 days after the provided by systemic TLR7 therapy may facilitate T cell priming to these antigens.
An important observation made during this study was the demonstration that the combination of R848 and fractionated RT resulted in significantly greater therapeutic efficacy in both the EG7 and EL4 models when compared to combination with a single dose RT, despite the higher radiobiological effect (RBE) and expected greater tumor cell lethality of the larger single dose. In the EL4 model, combination of a systemically administered TLR7 agonist with a fractionated course of 10 Gy RT delivered in 5 fractions of 2 Gy led to 100 % of mice rejecting their primary tumor (versus 15% when systemic TLR7 therapy was combined with a single dose of 10 Gy).
The mechanisms that underlie the differential efficacy observed following
For personal use only. on April 15, 2017. by guest www.bloodjournal.org From combination of TLR7 therapy and either single dose or fractionated RT are currently unclear and form the basis of ongoing studies. Interestingly, a study that profiled gene-expression in breast, prostate and glioma tumors after both single dose (10 Gy) and fractionated (5 fractions of 2 Gy) RT revealed significant changes in the tumor microenvironment with several genes including multiple interferon (IFN)-related genes uniquely upregulated following fractionated therapy 23 . Given that the induction of IFN is a major downstream effect of TLR7 agonism 24, 25 , combination with fractionated RT may lead to greater synergy and therapeutic response than with single-dose RT or monotherapy.
Although successful for the treatment of dermatological malignancy, the therapeutic efficacy of topically administered TLR7 agonists such as imiquimod (Aldara, Graceway Pharmaceuticals) is generally limited to the treatment site 26 .
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